Key result
Type 2 diabetes linked to ~2-point lower flow-mediated dilation versus healthy controls.
Why the study?
Does type 2 diabetes impair flow-mediated and glyceryl trinitrate-mediated vascular dilation compared to healthy matched controls?
Cross-Sectional (n=153)
No
Does type 2 diabetes impair flow-mediated and glyceryl trinitrate-mediated vascular dilation compared to healthy matched controls?
Absolute Event Rate: 4.52% vs 6.67%
p-value: p=<0.001
Combining NMD with FMD reveals that impaired vascular smooth muscle function is highly prevalent in type 2 diabetes, significantly compounding apparent endothelial dysfunction and correlating with albuminuria.
Type 2 diabetes was associated with impaired FMD and NMD; hypothesis-generating for combined assessment in risk stratification.
AIMS/INTRODUCTION: In order to characterize the impaired vascular function in type 2 diabetes (DM) patients, we evaluated the flow-mediated vascular dilation (FMD) with glyceryl trinitrate-mediated vascular dilation (NMD) using ultrasonography. MATERIALS AND METHODS: A total of 111 DM patients and 42 healthy control participants were studied. The maximal dilatation of FMD and NMD (%FMD and %NMD, respectively), the beginning time (T) of dilatation after stimulation and the velocity (V) of the vascular dilatation were also measured. RESULTS: Among DM patients, 49% had impaired %NMD, which affects the results of %FMD. In DM patients with normal %NMD, the %FMD was also significantly lower than that in control participants, although the T and the V were not impaired. In contrast, both the T and the V were disturbed in the DM patients with low %NMD. Multiple linear regression analysis showed that %NMD was independently correlated with albuminuria. Our results indicate that the impaired FMD in DM is be affected by low NMD, and impaired endothelial function already exists even in DM patients whose vascular smooth muscle function is still retained, and also albuminuria is the clinical feature of DM with low %NMD. CONCLUSIONS: Examination of NMD, not only FMD, should be carried out as it offers the possibility of clarifying vascular function in DM patients.
No takes yet. Share an insight, caveat, or question.
Furuta et al. (2012) conducted a cross-sectional in Type 2 diabetes (n=153). Type 2 diabetes vs. Healthy controls was evaluated on Maximal flow-mediated vascular dilation (%FMD) (p=<0.001). Type 2 diabetes reduced maximal flow-mediated vascular dilation (4.52% vs 6.67%, p<0.001) and glyceryl trinitrate-mediated dilation (10.7% vs 16.3%, p<0.001) compared to healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: